BioSight
Companies
ABEONA THERAPEUTICS INC. logo

ABEO

NASDAQCLEVELAND, OH
ABEONA THERAPEUTICS INC.

Abeona Therapeutics develops gene therapies using AAV (adeno-associated virus) vectors to treat ophthalmic diseases, with a commercialized product called ZEVASKYN and a pipeline of additional AAV-based candidates in clinical development. The company is at a mixed stage, having brought one product to market while continuing to advance earlier-stage gene therapy programs. Abeona depends on third-party vendors and partners for manufacturing, supply, and regulatory compliance across its operations.

Price history not yet available for ABEO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar